Skip to main content
Erschienen in: Acta Neuropathologica 5/2004

01.11.2004 | Regular Paper

DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q

verfasst von: M. Josefa Bello, Cinthia Amiñoso, Isabel Lopez-Marin, Dolores Arjona, Pilar Gonzalez-Gomez, M. Eva Alonso, Jesus Lomas, Jose M. de Campos, M. Elena Kusak, Jesus Vaquero, Alberto Isla, Manuel Gutierrez, Jose L. Sarasa, Juan A. Rey

Erschienen in: Acta Neuropathologica | Ausgabe 5/2004

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this research was to examine the DNA methylation profile of meningiomas. Accordingly, we examined the DNA methylation status of ten tumor-related genes (RB1, p16 INK4a , p73, MGMT, ER, DAPK, TIMP-3, p14 ARF , THBS1, and Caspase-8) in 98 meningiomas (68 grade I; 27 grade II; and 3 grade III samples) using methylation-specific PCR and sequencing. The most frequently methylated genes were THBS1 (30%), TIMP-3 (24%), p16 INK4a (17%), MGMT (16%), p73 (15%), ER (15%), and p14 ARF (13%), whereas methylation was relatively rare in the other genes (<10%). Methylation occurred in at least one gene in 77.5% of the cases and in three or more genes in 25.5%. Methylation was tumor specific since it was absent in the controls: two non-neoplastic meningeal samples and two non-neoplastic brain samples. The frequency of aberrant gene methylation in grade I versus grade II–III tumors showed some differences for TIMP-3, THBS1, MGMT, p16 INK4a and p73; these differences reached statistical significance for TIMP-3: 18% in grade I versus 40% in grade II–III (P<0.02). Our previous loss of heterozygosity studies provided the allelic constitution at 1p and 22q for 60 of the 98 meningiomas included in this report. The level of aberrant promoter methylation increased in tumors (30 samples) displaying 1p loss (either isolated or as concurrent deletion at 1p/22q; P=0.014). These meningiomas primarily accumulated the epigenetic changes of THBS1 (14/30; 47%; P<0.005), TIMP-3 (12/30; 40%; P<0.05), p73 (10/30; 26%; P<0.02) and p14 ARF /p16 INK4a (7/30 each one; 23%; not significant). Our findings indicate that aberrant DNA methylation of promoter-associated CpG islands in meningiomas contributes to the development of these tumors.
Literatur
1.
Zurück zum Zitat Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, Campos JM de, Isla A, Sarasa JL, Rey JA (2003) Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 144:134–142CrossRefPubMed Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, Campos JM de, Isla A, Sarasa JL, Rey JA (2003) Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 144:134–142CrossRefPubMed
2.
Zurück zum Zitat Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Campos JM de, Gutierrez M, Rey JA (2004) Aberrant CpG island methylaiton of multiple genes in ependymal tumors. J Neurooncol 67:159–165CrossRefPubMed Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Campos JM de, Gutierrez M, Rey JA (2004) Aberrant CpG island methylaiton of multiple genes in ependymal tumors. J Neurooncol 67:159–165CrossRefPubMed
3.
Zurück zum Zitat Amatya VJ, Takeshima Y, Inai K (2004) Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 17:705–710 Amatya VJ, Takeshima Y, Inai K (2004) Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 17:705–710
4.
Zurück zum Zitat Apte SS, Mattei M-G, Olsen BR (1994) Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 19:86–90CrossRefPubMed Apte SS, Mattei M-G, Olsen BR (1994) Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 19:86–90CrossRefPubMed
5.
Zurück zum Zitat Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR (1999) Methylation-associated silencing of the tissue inhibitor of Metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798–802PubMed Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR (1999) Methylation-associated silencing of the tissue inhibitor of Metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798–802PubMed
6.
Zurück zum Zitat Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in the DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196PubMed Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in the DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196PubMed
7.
Zurück zum Zitat Bello MJ, Campos JM de, Kusak ME, Vaquero J, Sarasa JL, Pestaña A, Rey JA (1994) Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9:296–298PubMed Bello MJ, Campos JM de, Kusak ME, Vaquero J, Sarasa JL, Pestaña A, Rey JA (1994) Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9:296–298PubMed
8.
Zurück zum Zitat Bello MJ, Campos JM de, Vaquero J, Kusak ME, Sarasa JL, Rey JA (2000) High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet 120:30–36CrossRefPubMed Bello MJ, Campos JM de, Vaquero J, Kusak ME, Sarasa JL, Rey JA (2000) High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet 120:30–36CrossRefPubMed
9.
Zurück zum Zitat Bello MJ, Alonso ME, Amiñoso C, Anselmo NP, Arjona D, Gonzalez-Gomez P, Lopez-Marin I, Campos JM de, Gutierrez M, Isla A, Kusak ME, Lassaletta L, Sarasa JL, Vaquero J, Casartelli C, Rey JA (2004) Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutation Res 554:23–32CrossRef Bello MJ, Alonso ME, Amiñoso C, Anselmo NP, Arjona D, Gonzalez-Gomez P, Lopez-Marin I, Campos JM de, Gutierrez M, Isla A, Kusak ME, Lassaletta L, Sarasa JL, Vaquero J, Casartelli C, Rey JA (2004) Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutation Res 554:23–32CrossRef
10.
Zurück zum Zitat Boström J, Meyer-Puttlitz B, Wolter M, Blschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G (2001) Alterations of the tumor suppressor genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in atypical and anaplastic meningiomas. Am J Pathol 159:661–669PubMed Boström J, Meyer-Puttlitz B, Wolter M, Blschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G (2001) Alterations of the tumor suppressor genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in atypical and anaplastic meningiomas. Am J Pathol 159:661–669PubMed
11.
Zurück zum Zitat Büschges R, Boström J, Wolter M, Blaschke B, Weber RG, Lichter P, Collins P, Reifenberger G (2001) Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18. Int J Cancer 92:551–554CrossRefPubMed Büschges R, Boström J, Wolter M, Blaschke B, Weber RG, Lichter P, Collins P, Reifenberger G (2001) Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18. Int J Cancer 92:551–554CrossRefPubMed
12.
Zurück zum Zitat Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A (2001) Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 60:628–636 Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A (2001) Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 60:628–636
13.
Zurück zum Zitat Corn PG, Kuerbitz SJ, Noesel MM van, Esteller M, Compitello N, Baylin SB, Herman JG (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’ CpG island methylation. Cancer Res 59:3352–3356PubMed Corn PG, Kuerbitz SJ, Noesel MM van, Esteller M, Compitello N, Baylin SB, Herman JG (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’ CpG island methylation. Cancer Res 59:3352–3356PubMed
14.
Zurück zum Zitat Costello JF, Plass C, Cavenee W (2000) Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol 17:49–56PubMed Costello JF, Plass C, Cavenee W (2000) Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol 17:49–56PubMed
15.
Zurück zum Zitat Dong S-H, Pang JC-S, Poon W-S, Hu J, To K-F, Chang AR, Ng H-K (2001) Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 60:808–816PubMed Dong S-H, Pang JC-S, Poon W-S, Hu J, To K-F, Chang AR, Ng H-K (2001) Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 60:808–816PubMed
16.
Zurück zum Zitat Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa J-PJ, Sidransky D, Baylin SB, Herman JG (2000) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368–2371PubMed Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa J-PJ, Sidransky D, Baylin SB, Herman JG (2000) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368–2371PubMed
17.
Zurück zum Zitat Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229PubMed Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229PubMed
18.
Zurück zum Zitat Esteller M, Risques R-A, Minoru T, Capella G, Moreno V, Peinado MA, Baylin SH, Herman JG (2001) Promoter hypermethylation of the DNA repair gen O6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 61:4689–4692PubMed Esteller M, Risques R-A, Minoru T, Capella G, Moreno V, Peinado MA, Baylin SH, Herman JG (2001) Promoter hypermethylation of the DNA repair gen O6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 61:4689–4692PubMed
19.
Zurück zum Zitat Gonzalez-Gomez P, Bello MJ, Alonso ME, Arjona D, Lomas J, Campos JM de, Isla A, Rey JA (2003) CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer 88:109–114CrossRefPubMed Gonzalez-Gomez P, Bello MJ, Alonso ME, Arjona D, Lomas J, Campos JM de, Isla A, Rey JA (2003) CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer 88:109–114CrossRefPubMed
20.
Zurück zum Zitat Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Arjona D, Campos JM de, Vaquero J, Isla A, Lassaletta L, Gutierrez M, Sarasa JL, Rey JA (2003) CpG island methylation in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Cancer Res 9:5601–5606 Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Arjona D, Campos JM de, Vaquero J, Isla A, Lassaletta L, Gutierrez M, Sarasa JL, Rey JA (2003) CpG island methylation in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Cancer Res 9:5601–5606
21.
Zurück zum Zitat Gonzalez-Gomez P, Bello MJ, Arjona D, Alonso ME, Lomas J, Campos JM de, Kusak ME, Gutierrez M, Sarasa JL, Rey JA (2003) Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas. Oncol Rep 10:1519–1523PubMed Gonzalez-Gomez P, Bello MJ, Arjona D, Alonso ME, Lomas J, Campos JM de, Kusak ME, Gutierrez M, Sarasa JL, Rey JA (2003) Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas. Oncol Rep 10:1519–1523PubMed
22.
Zurück zum Zitat Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, Campos JM de, Vaquero J, Isla A, Gutierrez M, Rey JA (2003) Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 22:601–608PubMed Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, Campos JM de, Vaquero J, Isla A, Gutierrez M, Rey JA (2003) Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 22:601–608PubMed
23.
Zurück zum Zitat Gonzalez-Gomez P, Bello MJ, Lomas J, Alonso ME, Amiñoso C, Lopez-Marin I, Anselmo NP, Sarasa JL, Gutierrez M, Casartelli C, Rey JA (2003) Aberrant methylation of multiple genes in neuroblastic tumours: relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 39:1478–1485CrossRefPubMed Gonzalez-Gomez P, Bello MJ, Lomas J, Alonso ME, Amiñoso C, Lopez-Marin I, Anselmo NP, Sarasa JL, Gutierrez M, Casartelli C, Rey JA (2003) Aberrant methylation of multiple genes in neuroblastic tumours: relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 39:1478–1485CrossRefPubMed
24.
Zurück zum Zitat Herman JG, Graff JR, Myohannen S, Nelkin BD, Baylin BD (1996) Methylation-specific PCR: a novel PCR assay for methylaiton status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826CrossRefPubMed Herman JG, Graff JR, Myohannen S, Nelkin BD, Baylin BD (1996) Methylation-specific PCR: a novel PCR assay for methylaiton status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826CrossRefPubMed
25.
Zurück zum Zitat Hong C, Bollen AW, Costello JF (2003) The contribution of genetic and epigenetic mechanisms to gene silencing in oligodendrogliomas. Cancer Res 63:7600–7605PubMed Hong C, Bollen AW, Costello JF (2003) The contribution of genetic and epigenetic mechanisms to gene silencing in oligodendrogliomas. Cancer Res 63:7600–7605PubMed
26.
Zurück zum Zitat Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, Saito N (2003) Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 22:7862–7865CrossRefPubMed Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, Saito N (2003) Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 22:7862–7865CrossRefPubMed
27.
Zurück zum Zitat Jiang SY, Jordan VC (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 65:163–168 Jiang SY, Jordan VC (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 65:163–168
28.
Zurück zum Zitat Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancer. Cell 90:809–819CrossRefPubMed Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancer. Cell 90:809–819CrossRefPubMed
29.
Zurück zum Zitat Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292–8297CrossRefPubMed Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292–8297CrossRefPubMed
30.
Zurück zum Zitat Kang GH, Shim Y-H, Jung H-Y, Kim WH, Ro JY, Rhyu M-G (2001) CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 61:2847–2851PubMed Kang GH, Shim Y-H, Jung H-Y, Kim WH, Ro JY, Rhyu M-G (2001) CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 61:2847–2851PubMed
31.
Zurück zum Zitat Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T, Saito Y, Kochi M, Kuratsu J, Saya H, Ushio Y (2001) Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 6:441–454CrossRefPubMed Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T, Saito Y, Kochi M, Kuratsu J, Saya H, Ushio Y (2001) Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 6:441–454CrossRefPubMed
32.
Zurück zum Zitat Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M (1999) Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 110:103–110CrossRefPubMed Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M (1999) Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 110:103–110CrossRefPubMed
33.
Zurück zum Zitat Leone PE, Bello MJ, Campos JM de, Vaquero J, Sarasa JL, Pestaña A, Rey JA (1999) NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18:2231–2239CrossRefPubMed Leone PE, Bello MJ, Campos JM de, Vaquero J, Sarasa JL, Pestaña A, Rey JA (1999) NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18:2231–2239CrossRefPubMed
34.
Zurück zum Zitat Li Q, Ahuja N, Burger PC, Issa J-PJ (1999) Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene 18:3284–3289CrossRefPubMed Li Q, Ahuja N, Burger PC, Issa J-PJ (1999) Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene 18:3284–3289CrossRefPubMed
35.
Zurück zum Zitat Lindblom A, Ruttledge M, Collins VP, Nordenskjold M, Dumanski JP (1994) Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 56:354–357PubMed Lindblom A, Ruttledge M, Collins VP, Nordenskjold M, Dumanski JP (1994) Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 56:354–357PubMed
36.
Zurück zum Zitat Lomas J, Amiñoso C, Gonzalez-Gomez P, Alonso ME, Arjona D, Lopez-Marin I, Campos JM de, Isla A, Vaquero J, Gutierrez M, Sarasa JL, Bello MJ, Rey JA (2004) Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet 148:148–151CrossRefPubMed Lomas J, Amiñoso C, Gonzalez-Gomez P, Alonso ME, Arjona D, Lopez-Marin I, Campos JM de, Isla A, Vaquero J, Gutierrez M, Sarasa JL, Bello MJ, Rey JA (2004) Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet 148:148–151CrossRefPubMed
37.
Zurück zum Zitat Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Callaghan R, Collado M, Roldan P, Llombart-Bosch A (2004) Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 148:123–128CrossRefPubMed Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Callaghan R, Collado M, Roldan P, Llombart-Bosch A (2004) Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 148:123–128CrossRefPubMed
38.
Zurück zum Zitat Louis DN, Scheithauer BW, Budka H, Deimling A von, Kepes JJ (2000) Meningioma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics. Tumours of the nervous system. World Health Organization classification of tumours. IARC Press, Lyon, pp 176–184 Louis DN, Scheithauer BW, Budka H, Deimling A von, Kepes JJ (2000) Meningioma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics. Tumours of the nervous system. World Health Organization classification of tumours. IARC Press, Lyon, pp 176–184
39.
Zurück zum Zitat Mihaila D, Gutierrez JA, Rosemblum ML, Newsham IF, Bogler O, Rempel SA (2003) Meningiomas: analysis of loss of heterozygosity on chromosome 10 in tumor progression and the delineation of four regions of chromosomal deletion in common with other cancers. Clin Cancer Res 9:4435–4442 Mihaila D, Gutierrez JA, Rosemblum ML, Newsham IF, Bogler O, Rempel SA (2003) Meningiomas: analysis of loss of heterozygosity on chromosome 10 in tumor progression and the delineation of four regions of chromosomal deletion in common with other cancers. Clin Cancer Res 9:4435–4442
40.
Zurück zum Zitat Murakami M, Hashimoto N, Takahashi Y, Hosokawa Y, Inazawa J, Mineura K (2003) A consistent region of deletion on 1p36 in meningiomas: identification and relation to malignant progression. Cancer Genet Cytogenet 140:99–106CrossRefPubMed Murakami M, Hashimoto N, Takahashi Y, Hosokawa Y, Inazawa J, Mineura K (2003) A consistent region of deletion on 1p36 in meningiomas: identification and relation to malignant progression. Cancer Genet Cytogenet 140:99–106CrossRefPubMed
41.
Zurück zum Zitat Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C to A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715–1719CrossRefPubMed Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C to A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715–1719CrossRefPubMed
42.
Zurück zum Zitat Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81:77–82PubMed Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81:77–82PubMed
43.
Zurück zum Zitat Natarajan AT, Vermeulen S, Darroudi F, Valentine MB, Brent TP, Mitra S, Tano K (1992) Chromosomal localization of human O(6)-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. Mutagenesis 7:83–85PubMed Natarajan AT, Vermeulen S, Darroudi F, Valentine MB, Brent TP, Mitra S, Tano K (1992) Chromosomal localization of human O(6)-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. Mutagenesis 7:83–85PubMed
44.
Zurück zum Zitat Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyltransferase regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119–6129PubMed Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyltransferase regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119–6129PubMed
45.
Zurück zum Zitat Powe DG, Brough JL, Carter GI, Bailey EM, Stetler-Stevenson WG, Turner DR, Hewitt RE (1997) TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer 75:1678–1683PubMed Powe DG, Brough JL, Carter GI, Bailey EM, Stetler-Stevenson WG, Turner DR, Hewitt RE (1997) TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer 75:1678–1683PubMed
46.
Zurück zum Zitat Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosemblum, ML (1993) Loss of heterozygosity for loci on chromosme 10 is associated with morphologically malignant meningioma progression. Cancer Res 53:2386–2392PubMed Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosemblum, ML (1993) Loss of heterozygosity for loci on chromosme 10 is associated with morphologically malignant meningioma progression. Cancer Res 53:2386–2392PubMed
47.
Zurück zum Zitat Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist P, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP, Dumanski JP, Rouleau GA (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180–184CrossRefPubMed Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist P, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP, Dumanski JP, Rouleau GA (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180–184CrossRefPubMed
48.
Zurück zum Zitat Simon M, Deimling A von, Larson JJ, Wellenreuther R, Kaskel P, Waha A, Warnick RE, Tew JM, Menon AG (1995) Allelic losses on chromosome 14, 10, and 1 in atypical and malignant meningiomas. A genetic model of meningioma progression. Cancer Res 55:4696–4701PubMed Simon M, Deimling A von, Larson JJ, Wellenreuther R, Kaskel P, Waha A, Warnick RE, Tew JM, Menon AG (1995) Allelic losses on chromosome 14, 10, and 1 in atypical and malignant meningiomas. A genetic model of meningioma progression. Cancer Res 55:4696–4701PubMed
49.
Zurück zum Zitat Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE (2000) Loss of pRB expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60:1211–1216PubMed Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE (2000) Loss of pRB expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60:1211–1216PubMed
51.
Zurück zum Zitat Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastoams with amplification of MYCN. Nat Med 6:529–535CrossRefPubMed Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastoams with amplification of MYCN. Nat Med 6:529–535CrossRefPubMed
52.
Zurück zum Zitat Tse JY, Ng HK, Lo KW, Lam PY, Ng EK, Poon WS, Huang DP (1998) Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas. Hum Pathol 29:1200–1207CrossRefPubMed Tse JY, Ng HK, Lo KW, Lam PY, Ng EK, Poon WS, Huang DP (1998) Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas. Hum Pathol 29:1200–1207CrossRefPubMed
53.
Zurück zum Zitat Uhlmann K, Rohde K, Zeller C, Szymas J, Vogel S, Marczinek K, Thiel G, Nürnberg P, Laird PW (2003) Distinct methylaiton profiles of glioma subtypes. Int J Cancer 106:52–59CrossRefPubMed Uhlmann K, Rohde K, Zeller C, Szymas J, Vogel S, Marczinek K, Thiel G, Nürnberg P, Laird PW (2003) Distinct methylaiton profiles of glioma subtypes. Int J Cancer 106:52–59CrossRefPubMed
54.
Zurück zum Zitat Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol 101:185–189PubMed Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol 101:185–189PubMed
55.
Zurück zum Zitat Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P (1997) Analysis of geneomic alterations in benign, atypical, and anaplastic meningiomas. Toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94:14719–14724CrossRefPubMed Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P (1997) Analysis of geneomic alterations in benign, atypical, and anaplastic meningiomas. Toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94:14719–14724CrossRefPubMed
56.
Zurück zum Zitat Wolter M, Reifenberger J, Blaschke B, Ichimura K, Schmidt EE, Collins VP, Reifenberger G (2001) Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 60:1170–1180PubMed Wolter M, Reifenberger J, Blaschke B, Ichimura K, Schmidt EE, Collins VP, Reifenberger G (2001) Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 60:1170–1180PubMed
57.
Zurück zum Zitat Xing EP, Nie Y, Song Y, Yang G-Y, Cai YC, Wang LD, Yang CS (1999) Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 5:2704–2713 Xing EP, Nie Y, Song Y, Yang G-Y, Cai YC, Wang LD, Yang CS (1999) Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 5:2704–2713
58.
Zurück zum Zitat Yin D, Xie D, Hofmann W-K, Miller CW, Black KL, Koeffler HP (2002) Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 21:8372–8378CrossRefPubMed Yin D, Xie D, Hofmann W-K, Miller CW, Black KL, Koeffler HP (2002) Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 21:8372–8378CrossRefPubMed
59.
Zurück zum Zitat Yin D, Xie D, Hofmann W-K, Zhang W, Asotra K, Wong R, Black KL, Koeffler HP (2003) DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinogenesis 36:23–31CrossRef Yin D, Xie D, Hofmann W-K, Zhang W, Asotra K, Wong R, Black KL, Koeffler HP (2003) DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinogenesis 36:23–31CrossRef
60.
Zurück zum Zitat Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61:249–255PubMed Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61:249–255PubMed
Metadaten
Titel
DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q
verfasst von
M. Josefa Bello
Cinthia Amiñoso
Isabel Lopez-Marin
Dolores Arjona
Pilar Gonzalez-Gomez
M. Eva Alonso
Jesus Lomas
Jose M. de Campos
M. Elena Kusak
Jesus Vaquero
Alberto Isla
Manuel Gutierrez
Jose L. Sarasa
Juan A. Rey
Publikationsdatum
01.11.2004
Verlag
Springer-Verlag
Erschienen in
Acta Neuropathologica / Ausgabe 5/2004
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-004-0911-6

Weitere Artikel der Ausgabe 5/2004

Acta Neuropathologica 5/2004 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.